HC Wainwright Reaffirms “Buy” Rating for Kura Oncology (NASDAQ:KURA)

HC Wainwright reiterated their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research note issued to investors on Monday, Benzinga reports. They currently have a $32.00 price target on the stock. HC Wainwright also issued estimates for Kura Oncology’s FY2025 earnings at ($2.96) EPS.

Several other equities research analysts have also recently weighed in on the stock. JMP Securities reaffirmed a market outperform rating and set a $32.00 price objective on shares of Kura Oncology in a research report on Tuesday, June 18th. StockNews.com downgraded Kura Oncology from a hold rating to a sell rating in a research note on Monday, April 15th. Finally, Wedbush reissued an outperform rating and set a $37.00 target price on shares of Kura Oncology in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $28.36.

Kura Oncology Trading Up 0.5 %

KURA opened at $20.60 on Monday. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The company has a 50-day simple moving average of $20.70 and a 200 day simple moving average of $19.20. The company has a quick ratio of 16.67, a current ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -9.49 and a beta of 0.94.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period last year, the company earned ($0.50) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. Analysts predict that Kura Oncology will post -2.56 EPS for the current fiscal year.

Insider Activity

In other news, insider Teresa Brophy Bair sold 2,615 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $22.15, for a total value of $57,922.25. Following the completion of the transaction, the insider now owns 68,979 shares of the company’s stock, valued at $1,527,884.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. 1492 Capital Management LLC increased its stake in shares of Kura Oncology by 1.0% in the fourth quarter. 1492 Capital Management LLC now owns 101,500 shares of the company’s stock valued at $1,460,000 after buying an additional 1,034 shares during the period. Signaturefd LLC increased its position in Kura Oncology by 40.4% during the 4th quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock valued at $72,000 after purchasing an additional 1,449 shares during the period. ProShare Advisors LLC increased its position in Kura Oncology by 9.7% during the 1st quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares during the period. Aaron Wealth Advisors LLC increased its position in Kura Oncology by 5.3% during the 4th quarter. Aaron Wealth Advisors LLC now owns 54,946 shares of the company’s stock valued at $790,000 after purchasing an additional 2,750 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its position in Kura Oncology by 17.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock valued at $430,000 after purchasing an additional 2,940 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.